We investigated the incidence of tympanic membrane (TM) perforations induced after intratympanic steroid injection (ITSI) in patients with sudden sensorineural hearing loss (SSNHL) through a systematic review and meta-analysis.
Data Sources
PubMed, Embase, and MEDLINE.
Review Methods
Primary database searches were performed, and 1901 records were identified. After removal of 1802 articles through abstract screening, the remaining 99 full-text journals were assessed for eligibility to be included in the study. Fifty-eight studies that used either ventilation tubing (VT) or tympanocentesis (TC) for ITSI were selected for analysis. The subjects were divided into VT and TC groups. The rate of TM perforation after ITSI in 2 groups, sites of ITSI, needle gauge, and influence on residual hearing were investigated.
Results
The cohorts comprised patients who underwent VT (n = 257, 9.6%) and TC (n = 2415, 90.4%). The proportion of TM perforation after ITSI in each group was 0.073 (95% CI, 0.0469-0.1113) and 0.010 (95% CI, 0.0045-0.0215), respectively, which suggested that the VT group showed a significantly higher TM perforation rate than the TC group (P < .001). In the subgroup analyses, there was no significant difference in the odds ratio for the rate of TM perforation according to the injection site and needle gauge for TC. The proportion of surgical repair showed no significant difference between the 2 groups.
Conclusion
ITSI via VT may have a significantly higher risk of TM perforation than ITSI via TC, although those are relatively small overall. ITSI should be performed in the direction to minimize possible adverse effects.
WuHPChouYFYuSHWangCPHsuCJChenPR.Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otol Neurotol. 2011;32(5):774-779.
4.
KimYHParkKTChoiBY, et al. Early combination treatment with intratympanic steroid injection in severe to profound sudden sensorineural hearing loss improves speech discrimination performance. Eur Arch Otorhinolaryngol. 2012;269(10):2173-2178.
5.
LeeJBChoiSJ.Potential benefits of combination therapy as primary treatment for sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2016;154(2):328-334.
6.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.
7.
TsengCCLaiMTWuCCYuanSPDingYF.Comparison of the efficacy of endoscopic tympanoplasty and microscopic tympanoplasty: a systematic review and meta-analysis. Laryngoscope. 2017;127(8):1890-1896.
8.
HigginsJPThompsonSGDeeksJJAltmanDG.Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
9.
HanCSParkJRBooSH, et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg. 2009;141(5):572-578.
10.
BattagliaABurchetteRCuevaR.Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2008;29(4):453-460.
11.
ArslanNOguzHDemirciM, et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2011;32(3):393-397.
12.
AhnJHWoul HanMHeui KimJWoo ChungJHyun YoonT. Therapeutic effectiveness over time of intratympanic dexamethasone as salvage treatment of sudden deafness. Acta Otolaryngol. 2008;128(2):128-131.
13.
AhnJHYooMHYoonTHChungJW.Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness?Laryngoscope. 2008;118(2):279-282.
14.
AlexanderTHHarrisJPNguyenQTVorasubinN.Dose effect of intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss: 24 mg/mL is superior to 10 mg/mL. Otol Neurotol. 2015;36(8):1321-1327.
BelhassenSSalibaI.Pain assessment of the intratympanic injections: a prospective comparative study. Eur Arch Otorhinolaryngol. 2012;269(12):2467-2473.
17.
BerjisNSoheilipourSMusaviAHashemiSM.Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Adv Biomed Res. 2016;5:111.
18.
ChenYWenLHuPQiuJLuLQiaoL.Endoscopic intratympanic methylprednisolone injection for treatment of refractory sudden sensorineural hearing loss and one case in pregnancy. J Otolaryngol Head Neck Surg. 2010;39(6):640-645.
19.
ChoILeeH-MChoiS-W, et al. Comparison of two different treatment protocols using systemic and intratympanic steroids with and without hyperbaric oxygen therapy in patients with severe to profound idiopathic sudden sensorineural hearing loss: a randomized controlled trial. Audiol Neurotol. 2018;23(4):199-207.
20.
CovelliEAltabaaKVerillaudB, et al. Intratympanic steroids as a salvage therapy for severe to profound idiopathic sudden sensorineural hearing loss. Acta Otolaryngol. 2018;138(11):966-971.
21.
CvorovicLJovanovicMBMilutinovicZArsovicNDjericD.Randomized prospective trial of hyperbaric oxygen therapy and intratympanic steroid injection as salvage treatment of sudden sensorineural hearing loss. Otol Neurotol. 2013;34(6):1021-1026.
22.
DahmVNieratschkerMRissD, et al. Intratympanic triamcinolone acetonide as treatment option for idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2019;40(6):720-727.
23.
DispenzaFAmodioEDe StefanoA, et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. Eur Arch Otorhinolaryngol. 2011;268(9):1273-1278.
24.
ErmutluGSusluNYilmazTSaracS.Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments. Eur Arch Otorhinolaryngol. 2017;274(10):3585-3591.
25.
FilipoRAttanasioGCagnoniL, et al. Long-term results of intratympanic prednisolone injection in patients with idiopathic sudden sensorineural hearing loss. Acta Otolaryngol. 2013;133(9):900-904.
26.
FilipoRAttanasioGRussoFY, et al. Oral versus short-term intratympanic prednisolone therapy for idiopathic sudden hearing loss. Audiol Neurootol. 2014;19(4):225-233.
27.
FilipoRCovelliEBalsamoGAttanasioG.Intratympanic prednisolone therapy for sudden sensorineural hearing loss: a new protocol. Acta Otolaryngol. 2010;130(11):1209-1213.
28.
FuYZhaoHZhangTChiF.Intratympanic dexamethasone as initial therapy for idiopathic sudden sensorineural hearing loss: clinical evaluation and laboratory investigation. Auris Nasus Larynx. 2011;38(2):165-171.
29.
GouverisHSelivanovaOMannW.Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy. Eur Arch Otorhinolaryngol. 2005;262(2):131-134.
30.
GundoganOPinarEImreAOzturkcanSCokmezOYigiterAC.Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngol Head Neck Surg. 2013;149(5):753-758.
31.
HaynesDSO’MalleyMCohenSWatfordKLabadieRF.Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope. 2007;117(1):3-15.
32.
Guan-MinHHung-ChingLMin-TsanSCheng-ChienYHsun-TienT.Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope. 2004;114(7):1184-1189.
33.
HongSMParkCHLeeJH.Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg. 2009;141(5):579-583.
34.
JiaHYuZLiX, et al. Efficacy of intratympanic corticosteroid, intravenous batroxobin and combined treatment for sudden sensorineural hearing loss with type-2 diabetes. Acta Otolaryngol. 2019;139(6):522-528.
35.
KakehataSSasakiAOjiK, et al. Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes. Otol Neurotol. 2006;27(5):604-608.
KiliçRSafakMAOguzH, et al. Intratympanic methylprednisolone for sudden sensorineural hearing loss. Otol Neurotol. 2007;28(3):312-316.
38.
KoltsidopoulosPBibasASismanisATzonouASeggasI.Intratympanic and systemic steroids for sudden hearing loss. Otol Neurotol. 2013;34(4):771-776.
39.
LabatutTDazaMJAlonsoA.Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2013;270(11):2823-2832.
40.
LiLRenJYinTLiuW.Intratympanic dexamethasone perfusion versus injection for treatment of refractory sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2013;270(3):861-867.
41.
LiPZengXLYeJYangQTZhangGHLiY.Intratympanic methylprednisolone improves hearing function in refractory sudden sensorineural hearing loss: a control study. Audiol Neurootol. 2011;16(3):198-202.
42.
OvetGAlatasNGuzelkaraF.Sudden pediatric hearing loss: comparing the results of combined treatment (intratympanic dexamethasone and systemic steroids) with systemic steroid treatment alone. Otol Neurotol. 2016;37(6):742-747.
43.
ParkMKLeeCKParkKHLeeJDLeeCGLeeBD.Simultaneous versus subsequent intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2011;145(6):1016-1021.
44.
QianYZhongSHuGKangHWangLLeiY.Sudden sensorineural hearing loss in children: a report of 75 cases. Otol Neurotol. 2018;39(8):1018-1024.
45.
RauchSDHalpinCFAntonelliPJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA. 2011;305(20):2071-2079.
46.
SelivanovaOAGouverisHVictorAAmedeeRGMannW.Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Meniere’s-associated sudden sensorineural hearing loss. Otol Neurotol. 2005;26(5):890-895.
47.
SiYJiangHLChenYB, et al. Round window niche drilling with intratympanic steroid is a salvage therapy of sudden hearing loss. Audiol Neurootol. 2018;23(6):309-315.
48.
SlatteryWHFisherLMIqbalZFriedmanRALiuN.Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg. 2005;133(2):251-259.
49.
SuzukiHHashidaKNguyenKH, et al. Efficacy of intratympanic steroid administration on idiopathic sudden sensorineural hearing loss in comparison with hyperbaric oxygen therapy. Laryngoscope. 2012;122(5):1154-1157.
50.
SuzukiHKoizumiHOhkuboJHohchiNIkezakiSKitamuraT.Hearing outcome does not depend on the interval of intratympanic steroid administration in idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2016;273(10):3101-3107.
51.
SuzukiHWakasugiTKitamuraTKoizumiHDoBHOhbuchiT.Comparison of 2 and 4 intratympanic steroid injections in the treatment of idiopathic sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol. 2018;127(4):235-240.
52.
SwachiaKSharmaDSinghJ.Efficacy of oral vs. intratympanic corticosteroids in sudden sensorineural hearing loss. J Basic Clin Physiol Pharmacol. 2016;27(4):371-377.
53.
TopfMCHsuDWAdamsDR, et al. Rate of tympanic membrane perforation after intratympanic steroid injection. Am J Otolaryngol. 2017;38(1):21-25.
54.
TsaiHTHsuehNHuangCMLinHC.Intratympanic steroid injection as a first-line therapy in uremia patients with sudden sensorineural hearing loss. Acta Otolaryngol. 2015;135(8):786-790.
55.
TsaiYJLiangJGWuWBDingYFChiangRPWuSM.Intratympanic injection with dexamethasone for sudden sensorineural hearing loss. J Laryngol Otol. 2011;125(2):133-137.
56.
TsounisMPsillasGTsalighopoulosMVitalVMaroudiasNMarkouK.Systemic, intratympanic and combined administration of steroids for sudden hearing loss: a prospective randomized multicenter trial. Eur Arch Otorhinolaryngol. 2018;275(1):103-110.
57.
XenellisJPapadimitriouNNikolopoulosT, et al. Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study. Otolaryngol Head Neck Surg. 2006;134(6):940-945.
58.
YangCHWuRWHwangCF.Comparison of intratympanic steroid injection, hyperbaric oxygen and combination therapy in refractory sudden sensorineural hearing loss. Otol Neurotol. 2013;34(8):1411-1416.
59.
YooMHLimWSParkJH, et al. Simultaneous versus sequential intratympanic steroid treatment for severe-to-profound sudden sensorineural hearing loss. Audiol Neurootol. 2016;21(6):399-405.
60.
ZhouYZhengHZhangQCampionePA.Early transtympanic steroid injection in patients with ‘poor prognosis’ idiopathic sensorineural sudden hearing loss. ORL J Otorhinolaryngol Relat Specialties. 2011;73(1):31-37.
61.
Al-ShehriA.Intratympanicvs.oral steroids for treatment of idiopathic sudden sensorineural hearing loss: a randomized controlled study. Br J Med Med Res. 2016;11(6):1-6.
62.
HoGMLinHCShuMTYangCCTsaiHT. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope. 2004;114:1184–1189.
JoSYLeeSEomTHJeunESChoHHChoYB.Outcomes of severe to profound idiopathic sudden sensorineural hearing loss. Clin Exp Otorhinolaryngol. 2015;8(3):206-210.
66.
SilversteinHChooDRosenbergSIKuhnJSeidmanMSteinI.Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J. 1996;75(8):468-471, 474, 476 passim.
67.
ParnesLSSunAHFreemanDJ.Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7, pt 2):1-17.
68.
NgJHHoRCMCheongCSJNgAYuenHWNgoRYS. Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? A meta-analysis. Eur Arch Otorhinolaryngol. 2015;272(10):2777-2782.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
